For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.
- Dosage of voglibose must be individualized on the basis of tolerance and effectiveness observed in patients. Total dose of maximum recommended dose of 0.6 mg, three times a day, should not be exceeded.
- In NIDDM patients, a dose of 0.2 mg tid before meals has been effective and it has been recommended. Voglibose should be co administered in conjunction with diet treatment or diet plus oral hypoglycaemic drugs and dose titration must be recommended only if a response is not seen with 0.2 mg tid of voglibose.
- The higher dose (0.3 mg three times daily) is effective in decreasing the reaction of VAT( visceral adipose tissue) to SATC (Subcutaneous Adipose Tissue) and glycaemic control was related to changes in VAT but not SATC.
- Some investigations recommend the use of voglibose only in patients who have an active satisfactory fasting glucose level (<140mg/dl) with strict diet plus sulfonylurea therapy, but who still have significant post-prandial glucose elevations (> 200mg/dl).
- For IDDM patients, dose of 0.2 to 0.3 mg tid before meals is administered along with insulin administration
- Hypersensitivity to the drug or to any of its components.
- Diabetic ketoacidosis.
- Inflammatory bowel diease, colonic ulcerations or partial intestinal obstructions and patients being predisposed to intestinal obstruction.
- Chronic disorders associated with marked disorders of digestion or absorption, with conditions that may deteriorate as a result of increased gas formation in the intestine.
- Pregnancy
- Lactating and Nursing Mothers
- Paediatric Use
- Liver Diseases
- Renal Function Impairment
- Gastro-Intestinal Disorders
- Endocrine and/or Metabolic Disorders
- Gastro Intestinal effects (<25%)
- Rise in liver enzymes (<20%)
- Nausea vomiting, dizziness
- Direct contact with heat, air and light may damage your medicines.
- Exposure to medicine may cause some harmful effects.
- The medicine must be kept in a safe place and out of children’s reach.
- Mainly the drug should be kept at room temperature between 68ºF and 77ºF (20ºC and 25ºC).
GLIBOSE 0.2 mg: 10×15’s
GLIBOSE 0.3 mg: 10×15’s
